The Oncology Institute Inc (TOI) reported its Q4 2024 earnings with revenue at $100.3 million, marking a 17% increase from Q4 2023. The full year revenue for 2024 was $393 million, which is 21.3% higher than the previous year. The Q4 2024 gross profit is $14.6 million, a 2% increase from Q4 2023, but the full year gross profit for 2024 was $54 million, a decrease of 9.4% from 2023. The company's SG&A expenses decreased by 12% in Q4 2024 compared to Q4 2023, and the full year SG&A for 2024 was $114 million, $5.6 million less than in 2023. The net loss for Q4 2024 was $13 million, which is $5.6 million better than Q4 2023, and the full year net loss for 2024 was $64.6 million, an improvement of $18.4 million from 2023. The Q4 2024 adjusted EBITDA was negative $7.8 million.

The Oncology Institute, Inc. (TOI) has announced a private placement of $16.5 million with its existing investors, management, and directors. The funds raised will be utilized for organic growth and as working capital. TOI has also entered into an exchange agreement with Deerfield Management Company, wherein convertible notes will be exchanged for preferred stock and warrants.

The Oncology Institute, Inc. has closed a private placement on March 26, 2025. This placement includes 12,006,510 shares of common stock, pre-funded warrants to purchase up to 2,886,614 shares of common stock, and common warrants to purchase up to 7,446,562 shares of common stock. The private placement is directed towards certain investors, including existing investors, members of the company's management team and board of directors, and entities affiliated with the board of directors.

1) Brief Summary: The Oncology Institute Inc. has displayed strong performance in the past quarter with a 365.00% increase and a monthly performance of 115.59%. However, the company exhibits a negative ROI of -44.16% and a highly negative ROE of -174.88%, indicating inefficient usage of resources. The company also has a high debt to equity ratio of 34.33, which could be concerning. Insider ownership is high at 51.27%, which usually indicates confidence in the company's future from those most familiar with it. The company's sales growth is solid, with a 21.33% year-over-year increase and a 16.88% quarter-over-quarter increase. Recent insider trading shows executives and entities purchasing both common stock and warrants, suggesting continued confidence in the company's prospects. 2) MARKET_SCORE: Given the strong recent performance, high insider ownership, and solid sales growth, despite the negative ROI and ROE, a MARKET_SCORE: 75

seems reasonable. 3) PRICE_TARGET: Based on the recent performance and strong sales growth, a moderate increase seems likely. If the current price is $1.5101, a 20% increase would result in a PRICE_TARGET: $1.81

. 4) AI_RPT_HEADLINE: "Oncology Institute Soars Despite Negative Returns, Bolstered by Insider Confidence"

-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes

====================================================== : 2025-04-02 11:41:40

# Analysis Completed Elapsed Time: 40.39 seconds